11.03.2022 - Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer’s Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) Lomecel-B for HLHS .
Rockley Photonics Announces Fourth Quarter and Full Year 2021 Financial Results – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Customer Demand Drives Early Introduction of Bioptx Biomarker Sensing Platform, Adding Professional Healthcare Solution to Previously Announced Consumer Wearables Solution, VitalSpex Rockley Ends
/PRNewswire/ Byrna Technologies Inc. (NASDAQ: BYRN) ("Byrna", "the Company", "we" or "us") today announced financial results for its fiscal fourth quarter.